Jade Biosciences filings document a Nasdaq-listed clinical-stage biotechnology issuer developing antibody therapies for autoimmune diseases. Form 8-K reports furnish operating and financial results and attach corporate updates covering JADE101, JADE201, JADE301, research progress, and liquidity-related disclosures.
The company's proxy and material-event filings cover annual meeting matters, board and officer changes, compensatory arrangements, employment inducement stock plans, material agreements, private placement securities, common stock and pre-funded warrant terms, and other capital-structure disclosures. The filings also identify Jade as an emerging growth company with common stock registered under the Exchange Act.
Jade Biosciences, Inc. director Mark Eisner reported receiving a stock option grant that gives him the right to buy 47,675 shares of common stock at an exercise price of $21.81 per share. All 47,675 option shares were reported as held directly after the grant.
The option expires on June 24, 2036. According to the footnote, 1/36 of the total option shares vest monthly after the grant date, as long as Eisner continues to provide service to the company on each vesting date. This structure turns the award into ongoing, service-based compensation rather than an immediate, fully vested position.
Jade Biosciences, Inc. director Mark Eisner filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing lists him as a director but does not report any buy, sell, or derivative transactions, indicating it is purely an initial ownership disclosure at this time.
Jade Biosciences, Inc. filed an 8-K announcing that its Board appointed Mark Eisner, M.D., M.P.H., as a Class I director effective June 25, 2026. He will serve until the 2028 annual meeting and join the Nominating and Corporate Governance Committee.
Dr. Eisner brings more than 25 years of leadership in clinical development and immunology, including senior roles at Vir Biotechnology, Sonoma Biotherapeutics, FibroGen and Genentech/Roche, as well as an academic career at UCSF. In connection with his appointment, he received a stock option to purchase 47,675 shares of Jade common stock under the 2025 Stock Incentive Plan, vesting in equal monthly installments over three years and accelerating upon a change in control, subject to continued service. He will also participate in the standard non-employee director compensation program and sign the company’s standard indemnification agreement. The company issued a press release with these details.
Jade Biosciences director Christopher W. Cain received a grant of stock options covering 34,843 shares of common stock at an exercise price of $15.22 per share. The option vests in full on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to his continued service.
Under an arrangement with Fairmount Funds Management LLC, Cain holds this option for one or more Fairmount investment funds and must turn over any net cash or stock to Fairmount for those funds. Both Cain and Fairmount disclaim beneficial ownership of the option and underlying shares.
DOBMEIER ERIC reported acquisition or exercise transactions in this Form 4 filing.
Jade Biosciences, Inc. director Eric Dobmeier received a stock option grant covering 34,843 shares of common stock. The option has a strike price of $15.22 per share and expires on June 8, 2036. It vests in full on June 9, 2027 or at the next annual stockholder meeting, subject to his continued service.
Jade Biosciences director Klein Lawrence Otto received a grant of stock options covering 34,843 shares of common stock. These options have an exercise price of $15.22 per share and expire on June 8, 2036. The award vests in full on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to his continued service. Following this compensation grant, he holds 34,843 derivative securities directly.
Jade Biosciences director Erin Lavelle received a stock option grant covering 34,843 shares of common stock. The option has an exercise price of $15.22 per share and expires on June 8, 2036. It vests in full on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to her continued service.
Jade Biosciences, Inc. reported a compensation-related insider transaction involving a stock option grant. Director Tomas Kiselak received an option covering 34,843 shares of common stock at an exercise price of $15.22 per share, with no cash paid for the grant itself.
The option vests in full on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to Kiselak’s continued service to the company. The option expires on June 8, 2036, giving a long-dated right to purchase shares once vested.
A footnote explains that Kiselak holds this option for one or more investment vehicles managed by Fairmount Funds Management LLC, and he must turn over any net cash or stock from the option to Fairmount for the benefit of the relevant Fairmount fund. Fairmount, Peter Harwin, and Kiselak each disclaim beneficial ownership of the securities except to the extent of any pecuniary interest.
Jade Biosciences, Inc. reported corporate governance changes following its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the Articles of Incorporation adding a new Article X that waives jury trials in certain circumstances, which became effective when the Amended and Restated Articles were filed with the Nevada Secretary of State on June 10, 2026.
The Board also approved Amended and Restated Bylaws, effective June 9, 2026, to modernize provisions in line with the Nevada Revised Statutes. Changes include removing the requirement to prepare a pre‑meeting stockholder list, expressly permitting virtual and remote stockholder and Board meetings, clarifying how record dates apply to postponed meetings, and redefining the voting standard for most stockholder actions so that the number of votes cast in favor must exceed the number of votes cast in opposition.
At the meeting, stockholders elected Christopher Cain, Ph.D. with 34,373,784 votes for and 8,041,605 withheld, and Tom Frohlich with 42,399,190 votes for and 16,199 withheld, along with approving other proposals that received strong majorities of votes cast.
Fairmount Funds and affiliated entities report beneficial ownership of 14,069,494 shares of Jade Biosciences common stock, representing 19.99% of the class. This stake includes 1,897,677 common shares and 9,516,000 shares issuable upon conversion of Series A non-voting convertible preferred stock held by Fairmount Healthcare Fund II L.P., plus 2,655,817 common shares held by Fairmount Healthcare Co-Invest IV L.P.
The filing states this Amendment No. 2 is being made solely to disclose a new lock-up agreement tied to the company’s underwritten public offering, and that the number of shares, pre-funded warrants, and preferred shares beneficially owned is unchanged from the prior amendment. In connection with the offering that closed on June 5, 2026, the reporting persons agreed not to sell company securities for 60 days following the date of the final prospectus supplement, unless the underwriters’ representatives consent. They did not purchase securities or otherwise participate in the offering.
The disclosure also notes that 5,790,206 common shares underlying pre-funded warrants and 3,106,000 shares issuable upon conversion of additional Series A preferred shares are excluded from beneficial ownership calculations due to 9.99% and 19.99% beneficial ownership limitations. Separately, stock options held by Tomas Kiselak to acquire 23,017 common shares at an exercise price of $10.14 per share vested and became exercisable on April 29, 2026.